Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

DNMT3A clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant

Christopher J. Gibson, MD, Haesook T. Kim, PhD, H. Moses Murdock, MD, Bryan Hambley, MD, Lin Zhao, MD, Lisa Green, PhD, Mark Fleharty, Brendan Blumenstiel, Carrie Cibulskis, BSc, Christopher D Gocke, MD, Sarah Nikiforow, MD PhD, Amy E. DeZern, MD, Vincent T. Ho, MD, Richard J. Jones, MD, Niall Lennon, PhD, Jerome Ritz, MD, Robert J. Soiffer, MD, Lukasz P. Gondek, MDPhD, R. Coleman Lindsley, MD PhD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-142925

Published: 2020

Journal Articles

ATM Germline Variant Increases the Risk of MPN Progression

Theodoros Karantanos, MD PhD, Shruti Chaturvedi, MBBS, MS, Christopher D Gocke, MD, Donna Marie Williams, PhD, Alison R. Moliterno, MD, Evan M Braunstein, MD PhD

Blood (2019) 134 (Supplement_1): 835.

https://doi.org/10.1182/blood-2019-125362

Published: 2019

Journal Articles

Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden

Theodoros Karantanos, MD PhD, Evan M Braunstein, MD PhD, Shruti Chaturvedi, MBBS, MS, Jerry L. Spivak, MD, Linda Resar, MD, Styliani Karanika, MD, Donna Marie Williams, PhD, Christopher D Gocke, MD, Alison R. Moliterno, MD

Blood (2019) 134 (Supplement_1): 837.

https://doi.org/10.1182/blood-2019-125393

Published: 2019

Journal Articles

Development of a Novel Next-Generation Sequencing (NGS)-Based Assay for Measurable Residual Disease (MRD) in FLT3 -ITD AML and Its Potential Clinical Application in Patients Treated with Chemotherapy Plus FLT3 Inhibitors

Mark J. Levis, MD, Wenge Shi, PhD, Ken CN Chang, PhD, Christian Laing, PhD, Flora Berisha, MS, Emily Adams, BS, MB(ASCP)CM, Christopher D Gocke, MD, Wei Ding, PhD, Kenji Nakamaru, Jelveh Lameh, PhD, Reinhold Pollner, Ken Kobayashi, MD

Blood (2018) 132 (Supplement 1): 1459.

https://doi.org/10.1182/blood-2018-99-110438

Published: 2018

Journal Articles

Germline ERBB2 Variants Associate with Myeloproliferative Neoplasms

Evan M Braunstein, MDPhD, Donna Marie Williams, PhD, Igor Makhlin, MD, Aparna Pallavajjala, Christopher D Gocke, MD, Nara Sobreira, MD, Kala Visvanathan, MD, Linda Resar, MD, Jerry L. Spivak, MD, Alison R. Moliterno, MD

Blood (2017) 130 (Supplement 1): 1663.

https://doi.org/10.1182/blood.V130.Suppl_1.1663.1663

Published: 2017

Journal Articles

Late-Relapse Diffuse Large B-Cell Lymphoma Frequently Represents Recurrence of the Original Disease, and Demonstrates Evidence of Superimposed Clonal Heterogeneity and Clonal Evolution

Rena R. Xian, MD, Genevieve M. Crane, MD PhD, Lisa M. Haley, Christopher D. Gocke, MD, Ming-Tseh Lin, MD PhD, Aparna Pallavajjalla, Michael J. Borowitz, MD PhD, Lode J. Swinnen, Amy S. Duffield, MD PhD

Blood (2014) 124 (21): 2955.

https://doi.org/10.1182/blood.V124.21.2955.2955

Published: 2014

NARROW

DNMT3A clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant

ATM Germline Variant Increases the Risk of MPN Progression

Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden

Development of a Novel Next-Generation Sequencing (NGS)-Based Assay for Measurable Residual Disease (MRD) in FLT3 -ITD AML and Its Potential Clinical Application in Patients Treated with Chemotherapy Plus FLT3 Inhibitors

Germline ERBB2 Variants Associate with Myeloproliferative Neoplasms

Late-Relapse Diffuse Large B-Cell Lymphoma Frequently Represents Recurrence of the Original Disease, and Demonstrates Evidence of Superimposed Clonal Heterogeneity and Clonal Evolution

Email alerts

ASH Publications

American Society of Hematology

DNMT3A clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant

ATM Germline Variant Increases the Risk of MPN Progression

Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden

Development of a Novel Next-Generation Sequencing (NGS)-Based Assay for Measurable Residual Disease (MRD) in FLT3 -ITD AML and Its Potential Clinical Application in Patients Treated with Chemotherapy Plus FLT3 Inhibitors

Germline ERBB2 Variants Associate with Myeloproliferative Neoplasms

Late-Relapse Diffuse Large B-Cell Lymphoma Frequently Represents Recurrence of the Original Disease, and Demonstrates Evidence of Superimposed Clonal Heterogeneity and Clonal Evolution

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only